Last updated: May 10, 2026
Who Supplies Piperacillin and Tazobactam in Duplex (Dual-Compartment) Containers?
What is the relevant product format for “duplex container”?
“Duplex container” is used in drug packaging to describe a dual-compartment container that separates two components until activation, then mixes them in a single administration container. For “piperacillin and tazobactam and sodium chloride in duplex container,” the packaging structure typically maps to:
- Compartment A: piperacillin and tazobactam (often as a lyophilized or reconstitutable powder)
- Compartment B: sodium chloride solution (diluent) used for reconstitution
This packaging format is most commonly sold as a combination reconstitution system, where the container design reduces dosing errors and improves mixing consistency versus separate vials.
Which supply categories matter for R&D and procurement?
For this specific drug + packaging format, suppliers split into two commercial lanes:
- Active ingredient and finished-dose/pharma packaging supply
- API and finished sterile drug product supply
- Sourcing of both the combination product and the dual-compartment container components (when integrated supply is used)
- Container system suppliers (drug-device packaging)
- Manufacturers of dual-compartment/duplex containers and their associated transfer and mixing mechanisms
- Suppliers of container materials and sterile closure/assembly systems
What supplier types cover “piperacillin and tazobactam and sodium chloride in duplex container”?
1) Finished-dose manufacturers that sell the duplex/dual-compartment reconstitution system
This is the most direct procurement path: the supplier provides the packaged, sterile combination product in the dual-compartment container format.
2) Packaging-system suppliers supplying duplex containers (container-only lane)
These suppliers provide the duplex containers that enable the product formulation to be filled and reconstituted inside the dual compartment. Container-only sourcing requires pairing with a pharma manufacturing site that can fill, seal, and release sterile product.
3) Contract manufacturers filling dual-compartment systems for branded or generic labels
In practice, many labels use contract sterile manufacturing where the drug product fill-finish happens at a CMOs site that can handle the duplex container format.
Supplier Identification: What can be stated from available evidence
No complete, verifiable supplier list can be produced from the information provided. You specified only the product descriptor, not:
- brand name(s) or market(s),
- exact container name (dual-compartment brand format),
- regulatory filings (MAA/NDA/BLA/SmPC/PIs),
- manufacturer of record,
- or country of authorization.
Without those, any attempt to name specific suppliers risks misattribution, especially because dual-compartment packaging is used across multiple antibiotic products and multiple container families, and suppliers vary by geography, tender structure, and label holder.
Therefore, no supplier names are provided.
Key Procurement Mapping (actionable structure without naming unverified suppliers)
If you are buying finished product
Your supplier due diligence should be structured as:
- Label holder / marketing authorisation holder (MAH): confirms the product configuration actually sold in your target market and packaging format.
- Manufacturer of record (MoR): confirms the sterile filling site and container system used.
- Batch documentation: confirms the container as released (dual-compartment, lot-level, closure system).
- Quality:
- sterility assurance method aligns with dual-compartment mixing,
- container compatibility data (extractables/leachables),
- reconstitution time and deliverable volume specifications.
If you are buying packaging-only duplex containers
Your due diligence should be structured as:
- Container system brand/family: dual-chamber architecture and transfer mechanism.
- Material compliance: typical targets include medical-grade polymer sets designed for parenteral use with validated compatibility for beta-lactams.
- Sterility and assembly validation: container cleanliness, sealing integrity, and leak testing methods.
- Filling compatibility: vacuum/pressure filling capability, powder handling for antibiotic solids, and solution compartment acceptance for sodium chloride.
Key Takeaways
- “Duplex container” implies a dual-compartment container that holds piperacillin/tazobactam separately from sodium chloride until mixing for parenteral administration.
- Supplier strategy splits into finished-dose manufacturers (most direct), container-only suppliers (packaging lane), and CMOs (fill-finish and assembly lane).
- A supplier list cannot be produced accurately from the descriptor alone; specific market/brand/container family identification is required to name suppliers without misattribution.
FAQs
1) Does “duplex container” always mean a dual-chamber reconstitution system?
Yes, in procurement language it indicates a dual-compartment container intended to mix contents during preparation for administration.
2) Is sodium chloride part of the final dosage or only the diluent for reconstitution?
It is typically a diluent compartment that enables reconstitution of the piperacillin/tazobactam component into an administration-ready solution.
3) Are packaging-system suppliers the same as drug manufacturers?
No. Packaging suppliers provide the duplex container systems; drug manufacturers or CMOs fill, seal, sterilize, and release the finished product.
4) Do suppliers vary by country and tender?
Yes. Packaging formats and container system families are frequently market-specific and can differ by tender and regulatory approvals.
5) What documentation proves the exact duplex container configuration?
The SmPC/PI packaging description, batch release documentation, and the MAH/MoR quality package that specifies the dual-compartment container.
References
[1] No sources were provided in the prompt, and no verifiable supplier evidence can be cited based on the limited descriptor alone.
